Search Within

Robert Motzer

  1. "Molecular Pharmacology and Chemistry Program Faculty"
Formats
  1. Meeting Abstract (9)
  2. Journal Article (6)
Groups
  1. Department of Medicine (15)
  2. Genitourinary Oncology Service (15)
  3. Molecular Pharmacology and Chemistry Program Faculty (15)
  4. Sloan Kettering Institute Faculty (15)
  5. Solid Tumor Oncology Division (15)
  6. GSK Faculty (14)

More Groups

People
  1. Steven Larson (10)
  2. Chaitanya Divgi (6)
  3. Lloyd Old (6)
  4. Sydney Welt (6)
  5. Darren Feldman (4)
  6. Neeta Pandit-Taskar (4)

More People

Years
  1. 2025 (1)
  2. 2023 (1)
  3. 2022 (1)
  4. 2016 (1)
  5. 2014 (1)
  6. 2013 (1)

More Years

Publications
  1. Journal of Clinical Oncology (4)
  2. Journal of Nuclear Medicine (4)
  3. Radiology (2)
  4. Bone Marrow Transplantation (1)
  5. European Journal of Cancer (1)
  6. European Journal of Nuclear Medicine (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (4)
  2. Society of Nuclear Medicine (4)
  3. Elsevier Inc. (2)
  4. Radiological Society of North America, Inc. (2)
  5. American Association for Cancer Research (1)
  6. Nature Publishing Group (1)

More Publishers

Results (15)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)Lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Renal cell carcinoma: A nomogram for the CT imaging-inclusive prediction of indolent, non-clear cell renal cortical tumours
    Journal Article

    Karlo, C. A.; Kou, L.; Di Paolo, P. L.; Kattan, M. W.; Motzer, R. J.; Russo, P.; Tickoo, S. K.; Akin, O.; Hricak, H.
    European Journal of Cancer (2016)

    Fulltext@MSK | Save
  • Radiogenomics of clear cell renal cell carcinoma: Associations between CT imaging features and mutations
    Journal Article

    Karlo, C. A.; Di Paolo, P. L.; Chaim, J.; Hakimi, A. A.; Ostrovnaya, I.; Russo, P.; Hricak, H.; Motzer, R.; Hsieh, J. J.; Akin, O.
    Radiology (2014)

    Fulltext@MSK | Save
  • Intra- and interobserver variability in CT measurements in oncology
    Journal Article

    McErlean, A.; Panicek, D. M.; Zabor, E. C.; Moskowitz, C. S.; Bitar, R.; Motzer, R. J.; Hricak, H.; Ginsberg, M. S.
    Radiology (2013)

    Fulltext@MSK | Save
  • (124)I-cG250 PET scan for early detection of response to sunitinib in patients (Pts) with metastatic clear cell renal cell carcinoma (MccRCC)
    Meeting Abstract

    Larson, S. M.; Motzer, R. J.; Pandit-Taskar, N.; Bartz, R.; Feldman, D. R.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma
    Journal Article

    Zelefsky, M. J.; Greco, C.; Motzer, R.; Magsanoc, J. M.; Pei, X.; Lovelock, M.; Mechalakos, J.; Zatcky, J.; Fuks, Z.; Yamada, Y.
    International Journal of Radiation Oncology, Biology, Physics (2012)

    Fulltext@MSK | Save
  • Phase I clinical trial with fractionated radioimmunotherapy using (131)I-labeled chimeric G250 in metastatic renal cancer
    Journal Article

    Divgi, C. R.; O'Donoghue, J. A.; Welt, S.; O'Neel, J.; Finn, R.; Motzer, R. J.; Jungbluth, A.; Hoffman, E.; Ritter, G.; Larson, S. M.; more...
    Journal of Nuclear Medicine (2004)

    Fulltext@MSK | Save
  • Fractionated radioimmunotherapy with I-131-labeled chimeric antibody G250 (cG250) in patients with metastatic renal cell carcinoma
    Meeting Abstract

    Divgi, C. R.; O'Donoghue, J. A.; McGagh, D. A.; Motzer, R. J.; Anwar, K.; Sheikh, A.; Gonzalez, R. S.; Welt, S.; Old, L. J.; Larson, S. M.
    Journal of Nuclear Medicine (1999)

    Fulltext@MSK | Save